Study of XIAP Antisense for Advanced Cancers

Inclusion Criteria: * histologically proven diagnosis of advanced or metastatic cancer (including solid tumours and lymphoma) * refractory to conventional treatment, or for which no conventional therapy exists with life expectancy of at least 12 weeks * ECOG performance status of 0 or 1 * hematological and biochemical indices as specified within one week prior to treatment Exclusion Criteria: * known bleeding diathesis or concurrent treatment with anticoagulants * primary brain tumours or brain metastases * radiotherapy (except palliative), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas and mitomycin-C) * all toxic manifestations of previous treatment must have resolved (excepting alopecia or certain Grade 1 toxicities) * pregnant or lactating women * major thoracic and/or abdominal surgery in the preceding 4 weeks * high medical risks from non-malignant systemic disease including uncontrolled infection * hepatitis B, C or Human Immunodeficiency Virus * allergic history to antisense agents